LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is leading efforts in addressing some of the pressing challenges in cancer treatment. “Instead of developing standalone cancer drugs, the company is adopting a different strategy aimed at enhancing the overall effectiveness of existing immunotherapy and chemotherapy regimens through a novel biological target,” reads a recent article. “LIXTE’s platform is built on its proprietary LB-100 compound, a one-of-a-kind inhibitor of Protein Phosphatase 2A (‘PP2A’). PP2A is a critical enzyme involved in various cellular processes, including cell growth regulation, DNA repair, and modulation of the immune response. Through the selective inhibition of PP2A, LB-100 is strategically designed to make cancer cells more treatable while also boosting the body’s immunity to tumors… This strategic approach is important because resistance and limited efficacy are major impediments in oncology. Different cancers fail to respond adequately to immunotherapy. The company’s strategy is not aimed at replacing these therapies, but rather at improving them, making it possible for standard treatments to work for more patients.”
NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at https://nnw.fm/LIXT
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer